Controversy in vitamin D dosing

As interest in vitamin D has greatly increased over the past decade given the many studies on this vitamin, doctors and patients seek credible sources of information to guide daily dosing. In November 2010, the Institute of Medicine (IOM), a non-profit group affiliated with the prestigious US National Academy of Sciences, issued a report that took an extremely conservative view on vitamin D. In essence, the report stated that the high blood levels of vitamin D advocated by many physicians and researchers were not necessary. Moreover, it generally suggested that most adults should be satisfied with a daily dosage between 400 and 600 IU of vitamin D.

In June 2011, the American Endocrine Society—an association of 14,000 researchers, physicians and other health and scientific professionals—issued comprehensive evidence-based guidelines that specifically focused on the use of vitamin D not just by healthy people, but also those people with chronic health conditions. Its analysis and recommendations are extensively covered in this issue of TreatmentUpdate. We have focused on the Endocrine Society’s guidelines in part because the Society has been regularly reviewing the literature on vitamin D research and also because it addresses the specific health needs of people living with HIV. Also, HIV-positive people appear to be at increased risk for thinner-than-normal bones and the Endocrine Society’s guidelines partially address that issue. Moreover, the Endocrine Society’s recommendations about dosing are similar to what scientists conducting clinical trials with HIV-positive people have found: Generally, larger-than-normal doses are required to raise vitamin D to levels associated with health, particularly skeletal health. Indeed, researchers at Toronto’s Hospital for Sick Children, commenting on their experience with a randomized trial of vitamin D supplementation in children with HIV, suggested that higher doses than those recommended by the IOM may be necessary in children and adults with HIV infection and perhaps other chronic medical conditions.

Usually the IOM’s reports are taken very seriously and set the agenda for a particular issue in North America and elsewhere. However, instead of addressing some of the confusion about vitamin D, the IOM’s report has triggered unease and in some cases outright unrest—unusual reactions to an IOM report.

Researcher and endocrinologist Michael Holick, based at Boston University’s School of Medicine, said: “The IOM was too definitive in its recommendations.” A proponent of evidence-based medicine, Canadian researcher and professor Gordon Guyatt from McMaster University said, “Basically, the [IOM’s] vitamin D recommendations are based on low-quality evidence.” He adds, “I think that admitting that would have made some of the angst disappear.”

In the past decade, because vitamin D has become associated with many health conditions, the “medical and scientific communities have become preoccupied with how it might prevent chronic disease,” reported the scientific journal Nature. The publication also noted that some physicians “recommend doses of up to 6,000 IU/day to make up for the time that people spend indoors. This is less than the amount a fair-skinned person without sunblock might make in half an hour of exposure to the midday summer sun.”

Not for everyone

According to Nature, the IOM’s mandate was to “set the levels [of vitamin D] that protect most people, but not all.” Furthermore, according to bone researchers in Germany and Switzerland and bio-statisticians in California, the IOM made a mathematical mistake in its calculations of the ideal level of vitamin D in the blood that is associated with strong bones. The IOM choose a level of 50 nmol/litre. However, an examination of the evidence suggests that setting the level of vitamin D at 75 nmol/litre (as done by the American Endocrine Society) would likely protect more people.

Members of the IOM’s panel stand by their calculations, saying that their methodology is “standard procedure for dietary recommendations.”
Tension about toxicity

One criticism of the IOM report is that it cited a clinical trial in which elderly women given 500,000 IU of vitamin D annually in a single dose experienced more falls and fractures than women of similar age who were given placebo. According to *Nature*, many researchers found that study “ridiculous.” Edward Giovannucci, a nutritional epidemiologist at the Harvard University School of Public Health, said, “No one absorbs 500,000 IU a day from the sun, so why would you give that as a supplemental dose?” But another Harvard University epidemiologist, JoAnn Manson, says that the mega-dose clinical trial should be factored into concerns about toxicity. She notes, “Within the first three weeks of this trial, when serum levels were at or above 100 nmol/litre, there was an increased risk of falls and fractures.”

Clinical trials to the rescue

Many clinical trials testing different doses and schedules of vitamin D are underway (some are mentioned later in this issue of *TreatmentUpdate*). Harvard’s JoAnn Manson is one of the scientists leading a five-year, 20,000-person study designed to assess the impact of vitamin D supplementation on cancer and cardiovascular disease.

Not all researchers are patient with the current pace of clinical trials of vitamin D. Reinhold Vieth, PhD, a world-renowned vitamin D scientist at the University of Toronto, calls the demand for huge clinical trials a “cop-out.” He says that there is good evidence that higher doses of vitamin D would reduce rates of multiple sclerosis, but a clinical trial to test this would require thousands of people and 30 years.”

Experts vs. data

*Nature* has suggested that the IOM panel members “underestimated the passion present in the vitamin D field.” Dr. Clifford Rosen, a member of the IOM panel and a respected member of the bone-research community, summarized the ongoing controversy about the IOM report as follows:

“This is the beginning of a whole new phase…. In the old days of medicine we believed experts, and now we say, show us the data.”

—Sean R. Hosein

REFERENCES:


Disclaimer

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question.

CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders.

Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs.

Permission to Reproduce

This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at 1.800.263.1638.

© CATIE

Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada.